Chemical: Drug
neomycin

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for neomycin

Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Caswell No. 595
  • Neomycin B Sulfate
  • Neomycin Sulfate
  • Neomycin Sulphate
  • Neomycin trisulfate salt hydrate
  • USAF CB-19
Trade Names
  • Biosol
  • Bykomycin
  • Endomixin
  • Fradiomycin
  • Fradiomycin Sulfate
  • Fraquinol
  • Lidamycin Creme
  • Myacine
  • Myacyne
  • Mycifradin
  • Mycifradin-N
  • Myciguent
  • Neo-Fradin
  • Neo-Mantle Creme
  • Neo-Rx
  • Neobiotic
  • Neobrettin
  • Neofracin
  • Neolate
  • Neomix
  • Neosulf
  • Nivemycin
  • Tuttomycin
  • Vonamycin Powder V
Brand Mixture Names
  • AK Spor liq (gramicidin + neomycin sulfate + polymyxin B sulfate)
  • AK Trol Suspension (dexamethasone + neomycin sulfate + polymyxin B sulfate)
  • Aminoderm Poudre (glycine + l-cysteine + neomycin sulfate + threonine)
  • Anaprime oph gel (flumethasone + neomycin sulfate + polymyxin B sulfate)
  • BNPH ont (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate)
  • Bacitracin-neomycin polymyxin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Bacitracin-neomycin-polymixin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Biosol-M-Aquadrops liq (methscopolamine bromide + neomycin sulfate)
  • Calf scour bolus (atropine sulfate + calcium phosphate + hyoscyamine sulfate + kaolin + neomycin sulfate + pectin + sulfaguanidine + sulfathiazole + vitamin A)
  • Certreat Scours Oblets (chlortetracycline hydrochloride + neomycin sulfate + nicotinic acid + vitamin A + vitamin D)
  • Cicatrin Powder (bacitracin zinc + glycine + l-cysteine + neomycin sulfate + threonine)
  • Co-op pinkeye spray (gentian violet + neomycin sulfate)
  • Cortisporin (bacitracin zinc + hydrocortisone + neomycin sulfate + polymyxin B sulfate)
  • Derma-4 ont (neomycin sulfate + nystatin + thiostrepton (antibiotic of a streptomyces species) + triamcinolone acetonide)
  • Dioptrol ointment (dexamethasone + neomycin sulfate + polymyxin B sulfate)
  • Diosporin ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Enterolyte (calcium chloride dihydrate + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • FML-Neo oph sus (fluorometholone + neomycin sulfate)
  • Forte topical suspension (hydrocortisone acetate + hydrocortisone sodium succinate + neomycin sulfate + penicillin g procaine + polymyxin B sulfate)
  • Kaobiotic bolus (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
  • Kaobiotic tab (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
  • Kenacomb (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Keraplex spray (methyl violet + neomycin sulfate)
  • Lidecomb cream (fluocinonide + gramicidin + neomycin sulfate + nystatin)
  • Mastitis Care (neomycin sulfate + penicillin g potassium + polymyxin B sulfate + streptomycin sulfate)
  • Maxitrol (dexamethasone + neomycin sulfate + polymyxin B sulfate)
  • Mecomb Cream 0.1% (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Mycitracin oph ont (bacitracin + neomycin sulfate + polymyxin B sulfate)
  • Neo Atropec 25 tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
  • Neo Atropec C tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
  • Neo Atropec tab (aluminum hydroxide + atropine methylnitrate + kaolin + neomycin sulfate + pectin + sulfacetamide + sulfaguanidine)
  • Neo Chlor Powder (neomycin sulfate + tetracycline hydrochloride)
  • Neo Darbazine Spansule Capsule no 1 (isopropamide iodide + neomycin sulfate + prochlorperazine maleate)
  • Neo Darbazine Spansule no 3 (isopropamide iodide + neomycin sulfate + prochlorperazine maleate)
  • Neo Oxymed Powder (neomycin sulfate + oxytetracycline hydrochloride)
  • Neo P.P.G. (neomycin sulfate + penicillin g potassium)
  • Neo Sulfa-E (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • Neo Sulfalyte Bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • Neo Terramycin Soluble Powder (neomycin sulfate + oxytetracycline hydrochloride)
  • Neo-Cortef (hydrocortisone acetate + neomycin sulfate)
  • Neo-Medrol (methylprednisolone acetate + neomycin sulfate)
  • Neo-Medrol Acne Lotion (aluminum chlorohydrate + methylprednisolone acetate + neomycin sulfate + sulfur)
  • Neo-Oxytetracycline (neomycin sulfate + oxytetracycline hydrochloride)
  • Neo-Terramycin 50/50 premix (neomycin sulfate + oxytetracycline hydrochloride)
  • Neo-Tet pws (neomycin sulfate + oxytetracycline hydrochloride)
  • Neodecadron Eye Ear Solution 0.1% (dexamethasone phosphate + neomycin sulfate)
  • Neomix-Pamine Solution (methscopolamine bromide + neomycin sulfate)
  • Neopaste (aluminum hydroxide + calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine + sulfathiazole)
  • Neorease (neomycin sulfate + sulfamethazine + sulfathiazole)
  • Neosol M Aquadrops (methscopolamine bromide + neomycin sulfate)
  • Neospan Mastitis Treatment (neomycin sulfate + penicillin g potassium + polymyxin B sulfate + streptomycin sulfate)
  • Neosporin Eye-Ear Solution (gramicidin + neomycin sulfate + polymyxin B sulfate)
  • Neosporin Irrigating Solution (neomycin sulfate + polymyxin B sulfate)
  • Neosporin Ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Neosporin Ophthalmic Ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Neosporin antibiotic cream (gramicidin + neomycin sulfate + polymyxin B sulfate)
  • Neosulf (neomycin sulfate + sulfamethazine + sulfathiazole)
  • Neosulf Plus bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • Neosulf bolus (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • Neosulpec (kaolin + neomycin + pectin + sulfaguanidine + sulfamethazine + sulfathiazole)
  • Neotet soluble concentrate (neomycin sulfate + oxytetracycline hydrochloride)
  • Neotetramed Powder (neomycin sulfate + tetracycline hydrochloride)
  • Neotopic ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Neovast tabs (kaolin + neomycin sulfate + pectin + sulfadiazine + sulfaguanidine + sulfamerazine + sulfathiazole)
  • Neox (neomycin sulfate + oxytetracycline hydrochloride)
  • Ophtacin ophtalmic ointment (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Ophtacin-H ophtalmic ointment (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B sulfate)
  • Optimyxin Plus Oto-opht GTTE (gramicidin + neomycin sulfate + polymyxin B sulfate)
  • Optiprime oph gel (neomycin sulfate + polymyxin B sulfate)
  • Optisone (neomycin + prednisolone)
  • Oribiotic ointment (bacitracin + lidocaine + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Otizol HC liq (hydrocortisone acetate + lidocaine hydrochloride + neomycin sulfate)
  • P.T. Booster (calcium d-pantothenate + neomycin sulfate + nicotinic acid + pyridoxine hydrochloride + streptomycin sulfate + vitamin A + vitamin B1 + vitamin B12 + vitamin B2 + vitamin D3)
  • Panolog cream (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
  • Panolog ointment (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
  • Pinkeye Spray (gentian violet + neomycin sulfate)
  • Previte (neomycin sulfate + selenium sulfide + streptomycin sulfate + vitamin A + vitamin D + vitamin e + vitamin K1)
  • Proctosone ont (dibucaine hydrochloride + esculin + hydrocortisone acetate + neomycin sulfate)
  • Proctosone sup (dibucaine hydrochloride + esculin + hydrocortisone acetate + neomycin sulfate)
  • Ratio-Triacomb regular cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Sandoz Cortimyxin (bacitracin zinc + hydrocortisone + neomycin sulfate + polymyxin B sulfate)
  • Scour Solution (methscopolamine bromide + neomycin sulfate)
  • Scour bolus plus (calcium carbonate + magnesium oxide + menadione sodium bisulfite + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + streptomycin sulfate + sulfamerazine + sulfamethazine + sulfanilamide + sulfathiazole + vitamin A + vitamin D)
  • Scour solution coop (methscopolamine bromide + neomycin sulfate)
  • Scour suspension (atropine sulfate + calcium phosphate + hyoscyamine sulfate + kaolin + neomycin sulfate + pectin + succinylsulfathiazole)
  • Scour treat liq (neomycin sulfate + sulfamethazine + sulfathiazole)
  • Scour-plug (calcium chloride + magnesium chloride + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + sulfamethazine)
  • Septomixine Forte (dexamethasone + halethazole tartrate + neomycin sulfate + polymyxin B sulfate + tyrothricin)
  • Solvaderm ointment (neomycin sulfate + nystatin + thiostrepton [antibiotic of a streptomyces species] + triamcinolone acetonide)
  • Spor-HC otic susp (hydrocortisone + neomycin sulfate + polymyxin B sulfate)
  • Sulectim plus scour boluses (calcium carbonate + magnesium oxide + menadione sodium bisulfite + neomycin sulfate + potassium acetate + sodium acetate + sodium chloride + streptomycin sulfate + sulfamerazine + sulfamethazine + sulfanilamide + sulfathiazole sodium + vitamin A + vitamin D)
  • Sulkamycin S Bolettes (neomycin sulfate + sulfamethazine)
  • Synalar Bi-otic solution (fluocinolone acetonide + neomycin sulfate + polymyxin B sulfate)
  • Theraderm cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Tresaderm dermatologic solution (dexamethasone + neomycin sulfate + thiabendazole)
  • Triple sulfa plus neomycin (neomycin sulfate + sulfamerazine sodium + sulfamethazine sodium + sulfathiazole sodium)
  • Vetropolycin HC ont (bacitracin zinc + hydrocortisone acetate + neomycin sulfate + polymyxin B)
  • Vetropolycin ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • Viaderm KC Cream (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Viaderm KC ont (gramicidin + neomycin sulfate + nystatin + triamcinolone acetonide)
  • Wound & Pinkeye Spray (gentian violet + neomycin sulfate)
  • bacitracin-neomycin-polymyxin oph ont (bacitracin zinc + neomycin sulfate + polymyxin B sulfate)
  • beef cattle vit ade premix medicated (neomycin sulfate + oxytetracycline hydrochloride + vitamin A + vitamin D3 + vitamin e)
  • dioptrol suspension (dexamethasone + neomycin sulfate + polymyxin B sulfate)
  • neo-chlor (neomycin sulfate + tetracycline hydrochloride)

PharmGKB Accession Id

PA450608

Type(s):

Drug

Description

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

Source: Drug Bank

Indication

Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

Source: Drug Bank

Pharmacology

Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Neomycin undergoes negligible biotransformation after parenteral administration.

Source: Drug Bank

Protein Binding

Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.

Source: Drug Bank

Absorption

Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.

Source: Drug Bank

Half-Life

2 to 3 hours

Source: Drug Bank

Toxicity

LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.

Source: Drug Bank

Route of Elimination

The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function.

Source: Drug Bank

Chemical Properties

Chemical Formula

C23H46N6O13

Source: Drug Bank

Average Molecular Weight

614.6437

Source: Drug Bank

Monoisotopic Molecular Weight

614.312285588

Source: Drug Bank

SMILES

C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N

Source: PubChem

InChI String

InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1

Source: PubChem

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
MT-RNR1

Drug Interactions

Interaction Description
cefotaxime - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefotaxime - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefotetan - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - neomycin Increased risk of nephrotoxicity (source: Drug Bank )
ticarcillin - neomycin Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line. (source: Drug Bank )

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ototoxicity

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to neomycin: 60

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Allele-specific PCR for detecting the deafness-associated mitochondrial 12S rRNA mutations. Gene. 2016. Ding Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Is deafness mutation screening required in cystic fibrosis patients?. Paediatric respiratory reviews. 2016. Abusamra Rania, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis. Journal of medical genetics. 2015. Jing Wu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Audio Profiles in Mitochondrial Deafness m.1555A>G and m.3243A>G Show Distinct Differences. Medical science monitor : international medical journal of experimental and clinical research. 2015. Iwanicka-Pronicka Katarzyna, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?. International journal of pediatric otorhinolaryngology. 2014. Al-Malky Ghada, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. BMC pediatrics. 2014. Göpel Wolfgang, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Heteroplasmy levels of mtDNA1555A>G mutation is positively associated with diverse phenotypes and mutation transmission in a Chinese family. Biochemical and biophysical research communications. 2012. Shen Shan-Shan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Unique penetrance of hearing loss in a five-generation Chinese family with the mitochondrial 12S rRNA 1555A > G mutation. Acta oto-laryngologica. 2011. Men Meichao, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The prevalence of mitochondrial mutations associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. The Laryngoscope. 2011. Ealy Megan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Molecular epidemiological analysis of mitochondrial DNA12SrRNA A1555G, GJB2, and SLC26A4 mutations in sporadic outpatients with nonsyndromic sensorineural hearing loss in China. Acta oto-laryngologica. 2011. Ji Yu-bin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Detection of deafness-causing mutations in the Greek mitochondrial genome. Disease markers. 2011. Kokotas Haris, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial 12S rRNA variants in 1642 Han Chinese pediatric subjects with aminoglycoside-induced and nonsyndromic hearing loss. Mitochondrion. 2010. Lu Jianxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic mutations and aminoglycoside-induced ototoxicity in neonates. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2010. Johnson Romaine F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochemical and biophysical research communications. 2010. Rydzanicz Małgorzata, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extensive and rapid screening for major mitochondrial DNA point mutations in patients with hereditary hearing loss. Journal of human genetics. 2010. Kato Tomofumi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial haplotypes may modulate the phenotypic manifestation of the deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion. 2010. Lu Jianxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial haplotype and phenotype of 13 Chinese families may suggest multi-original evolution of mitochondrial C1494T mutation. Mitochondrion. 2009. Zhu Yuhua, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial tRNA(Glu) A14693G variant may modulate the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in a Han Chinese family. Journal of genetics and genomics = Yi chuan xue bao. 2009. Ding Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation analysis of mitochondrial DNA 12SrRNA and tRNASer(UCN) genes in non-syndromic hearing loss patients. Mitochondrion. 2008. Konings Annelies, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenetics and genomics. 2008. Conrad Douglas J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial tRNAThr G15927A mutation may modulate the phenotypic manifestation of ototoxic 12S rRNA A1555G mutation in four Chinese families. Pharmacogenetics and genomics. 2008. Wang Xinjian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. Human mutation. 2008. Ballana Ester, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Whole mitochondrial genome screening in maternally inherited non-syndromic hearing impairment using a microarray resequencing mitochondrial DNA chip. European journal of human genetics : EJHG. 2007. Lévêque Marianne, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Coexistence of mitochondrial 12S rRNA C1494T and CO1/tRNA(Ser(UCN)) G7444A mutations in two Han Chinese pedigrees with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2007. Yuan Huijun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited aminoglycoside-induced and nonsyndromic hearing loss is associated with the 12S rRNA C1494T mutation in three Han Chinese pedigrees. Gene. 2007. Chen Jianfu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The mitochondrial tRNA(Ala) T5628C variant may have a modifying role in the phenotypic manifestation of the 12S rRNA C1494T mutation in a large Chinese family with hearing loss. Biochemical and biophysical research communications. 2007. Han Dongyi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Very low penetrance of hearing loss in seven Han Chinese pedigrees carrying the deafness-associated 12S rRNA A1555G mutation. Gene. 2007. Tang Xiaowen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Molecular and clinical characterisation of three Spanish families with maternally inherited non-syndromic hearing loss caused by the 1494C->T mutation in the mitochondrial 12S rRNA gene. Journal of medical genetics. 2006. Rodríguez-Ballesteros M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants in mitochondrial tRNAGlu, tRNAArg, and tRNAThr may influence the phenotypic manifestation of deafness-associated 12S rRNA A1555G mutation in three Han Chinese families with hearing loss. American journal of medical genetics. Part A. 2006. Young Wie-Yen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA T1095C mutation in three Chinese families. Biochemical and biophysical research communications. 2006. Dai Pu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. Biochemical and biophysical research communications. 2006. Bravo Olga, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochemical and biophysical research communications. 2006. Ballana Ester, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical and molecular analysis of a four-generation Chinese family with aminoglycoside-induced and nonsyndromic hearing loss associated with the mitochondrial 12S rRNA C1494T mutation. Biochemical and biophysical research communications. 2006. Wang Qiuju, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: implication for early detection and prevention of deafness. Biochemical and biophysical research communications. 2006. Dai Pu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical evaluation and mitochondrial DNA sequence analysis in two Chinese families with aminoglycoside-induced and non-syndromic hearing loss. Biochemical and biophysical research communications. 2005. Zhao Lidong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic features, clinical phenotypes, and prevalence of sensorineural hearing loss associated with the 961delT mitochondrial mutation. Auris, nasus, larynx. 2005. Kobayashi Katsuhiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. Human genetics. 2005. Li Zhiyuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extremely low penetrance of hearing loss in four Chinese families with the mitochondrial 12S rRNA A1555G mutation. Biochemical and biophysical research communications. 2005. Young Wie-Yen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical evaluation and sequence analysis of the complete mitochondrial genome of three Chinese patients with hearing impairment associated with the 12S rRNA T1095C mutation. Biochemical and biophysical research communications. 2004. Zhao Lidong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Audiovestibular findings in patients with mitochondrial A1555G mutation. The Laryngoscope. 2004. Noguchi Yoshihiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. American journal of human genetics. 2004. Zhao Hui, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cosegregation of C-insertion at position 961 with the A1555G mutation of the mitochondrial 12S rRNA gene in a large Chinese family with maternally inherited hearing loss. American journal of medical genetics. Part A. 2004. Li Ronghua, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss. Journal of medical genetics. 2003. del Castillo F J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Atypical muscle pathology and a survey of cis-mutations in deaf patients harboring a 1555 A-to-G point mutation in the mitochondrial ribosomal RNA gene. Neuromuscular disorders : NMD. 2002. Yamasoba Tatsuya, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation A1555G in the 12S rRNA gene and its epidemiological importance in German, Hungarian, and Polish patients. Human mutation. 2002. Kupka Susan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Maternally inherited deafness associated with a T1095C mutation in the mDNA. European journal of human genetics : EJHG. 2001. Tessa A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Different clinical characteristics of aminoglycoside-induced profound deafness with and without the 1555 A-->G mitochondrial mutation. ORL; journal for oto-rhino-laryngology and its related specialties. 2001. Tono T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Annals of neurology. 2000. Thyagarajan D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prevalence of mitochondrial gene mutations among hearing impaired patients. Journal of medical genetics. 2000. Usami S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Aminoglycoside-induced deafness associated with the mitochondrial DNA mutation A1555G. American journal of otolaryngology. 1999. Shohat M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cochlear implantation in a patient with profound hearing loss with the A1555G mitochondrial mutation. The American journal of otology. 1998. Tono T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Hearing loss due to the mitochondrial A1555G mutation in Italian families. American journal of medical genetics. 1998. Casano R A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. American journal of human genetics. 1998. Estivill X, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Familial streptomycin ototoxicity in a South African family: a mitochondrial disorder. Journal of medical genetics. 1997. Gardner J C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. The Laryngoscope. 1997. Usami S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. Journal of medical genetics. 1997. Pandya A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. American journal of otolaryngology. 1997. Fischel-Ghodsian N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic acids research. 1993. Hutchin T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nature genetics. 1993. Prezant T R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. American journal of otolaryngology. 1993. Fischel-Ghodsian N, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
39822-0310-5
DrugBank:
DB00994
PDB:
CNY
ChEBI:
7507
KEGG Compound:
C00384
PubChem Compound:
8378
PubChem Substance:
158283
46505525
IUPHAR Ligand:
709
Drugs Product Database (DPD):
527750
ChemSpider:
8075
HET:
CNY
Therapeutic Targets Database:
DAP000036
FDA Drug Label at DailyMed:
a35a558c-7d96-43fb-917b-475189772edd

Clinical Trials

These are trials that mention neomycin and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.